Fatigue in COPD: association with Functional Status and Hospitalisations.

J.S. Paddison\textsuperscript{a}, T.W. Effing\textsuperscript{a,b}, S. Quinn\textsuperscript{b} P.A. Frith\textsuperscript{a,b}

\textsuperscript{a} Repatriation General Hospital, Department of Respiratory Medicine, Adelaide, South Australia, Australia.

\textsuperscript{b} School of Medicine, Flinders University, Adelaide, South Australia, Australia.

Details of corresponding author:
Johanna Paddison
Respiratory Function Unit
Repatriation General Hospital
Daws Road
Daw Park
Adelaide 5041
South Australia
Email: johanna.paddison@health.sa.gov.au
Abstract

The research aims: To examine the importance of fatigue as a clinical indicator in COPD, by analysing its relationship to COPD severity and ability to predict risk of hospitalisation; and by comparing the intensity of fatigue in stable COPD patients with levels of fatigue reported by patients with other chronic conditions.

Patients and Methods: 100 consecutive patients attending assessment clinics before pulmonary rehabilitation. Both questionnaire and physiologic data were collected. Partial correlations, multiple linear regressions, and Cox proportional hazard models/negative binomial regressions were used to address the research questions.

Results: A significant relationship existed between fatigue and COPD severity. Fatigue reports predicted future hospitalisation risk. Compared to the lowest third of patients, the third of patients reporting the most intense fatigue showed a 10 fold increase in risk of hospitalisation (fatigue experiences HR: 10.2 95%CI 2.66-38.86; fatigue impacts HR: 10.7 95%CI 2.76-41.65). Our COPD sample reported fatigue scores of similar intensity to colorectal cancer patients and HIV-positive patients.

Conclusions: While fatigue is significantly related to COPD functional severity, fatigue data also capture independent information. Fatigue reports can contribute to predictions of hospitalisation risk.
**Introduction**

In clinical interactions fatigue frequently emerges as a prominent issue for patients living with COPD. Fatigue has been reported as the second most prevalent symptom after dyspnoea [1]. Yet the clinical significance of fatigue reports has received much less intensive investigation than other respiratory and systemic expressions of COPD, such as dyspnoea, decreases in body-mass, exercise capacity, muscle strength or increases in airflow obstruction. We therefore designed this study with three aims - to examine the relationship between fatigue and COPD severity; to investigate the ability of fatigue to predict risk of future hospitalisation; and to compare the intensity of fatigue in stable COPD patients with the levels of fatigue reported by patients with other chronic conditions.

Fatigue can refer to a physical or a mental state; or a combination of these. In this study we assessed fatigue using a validated comprehensive questionnaire. The Identity-Consequences Fatigue Scale (ICFS), a self-report tool, assesses five domains of fatigue (feelings of fatigue, feelings of vigour, impacts on concentration, impacts on energy, and impacts on daily activities), and provides two summary scores: fatigue experiences and fatigue impacts [2, 3]. Because the ICFS is a generic fatigue questionnaire, it allows comparisons to be made between different patient populations.

Associations between fatigue and disease severity have been reported in other chronic diseases such as chronic heart failure [4] and psoriatic arthritis [5]. Fatigue has been related to quality of life and functional limitation [6], but the association between fatigue and disease severity is less clear. Of the studies identified, several used the composite BODE score (2) as a proxy for COPD
severity [7, 8]. The BODE score incorporates four components previously identified as independent predictors of prognosis in COPD: body mass, level of airflow obstruction, disablement due to dyspnoea, and exercise capacity [9]. Its composite is a better prognostic index of outcome than any of its components.

The clinical value of fatigue in patients with COPD still needs to be determined. Might there be added value for the clinician to be more analytical when a patient reports fatigue? Previously fatigue reports have been shown to predict the time to death of terminally ill lung cancer patients [10] but no data have been published about the predictive value of fatigue in patients with COPD.

In examining the importance of fatigue reports in COPD patients we first examined whether patient-reported fatigue can predict the risk of future hospitalisation. Second, we examined the relationship between fatigue and severity of COPD. Finally, we compared the severity of fatigue measured using the ICFS in COPD patients to other chronic disease populations (patients with colorectal cancer and Human Immunodeficiency Virus (HIV)).

**Methods**

In this project a sample of 100 consecutive patients were recruited. These patients were attending an assessment clinic prior to entry to a pulmonary rehabilitation program at the Repatriation General Hospital, Adelaide, South Australia (Jan-Dec 2008). Ethical permission was gained from the Flinders Clinical Research Ethics Committee, South Australia. Data collected included
demographic variables, fatigue data, measures of COPD severity, and prospectively recorded hospital admissions.

**Fatigue Assessment**

The ICFS, a 31-item self-report tool, assesses five domains of fatigue (feelings of fatigue, feelings of vigour, impacts on concentration, impacts on energy, and impacts on daily activities), and provides two summary scores: fatigue experiences and fatigue impacts [2, 3]. The fatigue experiences score is the average of the feelings of fatigue, feelings of vigour, and impacts on concentration subscales. The fatigue impacts score is the average of the impacts on energy and impacts on daily activities subscales. For this work scores were generated on a scale from 0-10 (higher score = greater fatigue).

**Measures of COPD Clinical State**

Level of airflow obstruction was obtained from measurement of the forced expiratory volume in one second (FEV₁) using post bronchodilator efforts, according to ATS/ERS quality performance criteria [13], and using prediction equations for sex, age and height [14]. Disablement due to breathlessness was assessed using the modified Medical Research Council (mMRC) Dyspnoea Scale [15]. This measure assesses dyspnoea on a five-point scale with descriptive anchors ranging from 0 = ‘not troubled by breathlessness except on strenuous exercise’ to 4 = ‘too breathless to leave the house, or breathless when dressing or undressing’. Exercise capacity was obtained from the six-minute walk distance (6MWD), assessed using the ATS protocol; scoring was taken from meters walked [16]. Body Mass Index (BMI) was calculated as weight divided by squared height (kg/m²), obtained from fully clothed participants with shoes removed.
BODE scores were calculated according to the instructions of Celli et al. [9]. Participants’ BMI were categorized as 0 (≥ 21.1) or 1 (≤ 21); their FEV₁ % of predicted values were scored as: ≥ 65 = 0; 64-50 = 1; 49-36 = 2; and ≤ 35 = 3; raw scores for mMRC were used (scores 0 to 4), as detailed above. Participants’ 6MWDs (meters) were categorized as ≥ 350 meters = 0; 349-250 meters = 1; 249-150 meters = 2; and ≤ 149 meters = 3. Following these ratings, the component scores were summed to give a BODE index score, covering the range from 0 (= normal functional status) to 10 (= maximal functional impairment).

**Comparison of COPD fatigue levels with two other chronic disease populations**

The ICFS data from respiratory patients with complete datasets (N=83) were compared with two previously published datasets: 1) 38 colorectal cancer patients awaiting surgery recruited from out-patient clinics at Middllemore Hospital, Auckland, New Zealand [11]; and 2) 38 HIV-positive patients recruited from out-patient clinics at Massachusetts General Hospital, Boston, USA [12].

**Hospital Admission Data**

Electronic hospital records at the patients’ local tertiary centres (Flinders Medical Centre and Repatriation General Hospital) were examined. The period was 20 months from the date of study recruitment. Any inpatient admission with an ICD-10 code from the Respiratory “J” group listed as the primary diagnosis was recorded [17]. The number of admissions and associated lengths of stay were recorded.
**Statistical Analyses**

Partial correlations, adjusting for age and sex, were used to assess the associations between BODE, and fatigue experiences and fatigue impacts. For this analysis fatigue impacts was transformed by taking the square root to meet normality assumptions. Fatigue experiences and BODE were normally distributed.

Time to hospitalisation was investigated using a Cox proportional Hazard shared frailty models, clustering over individuals to account for correlated observations, and adjusting for age, gender, BODE, and either fatigue experiences or fatigue impacts. That is, the effects of fatigue experiences and fatigue impacts were examined in separate models. Initially, each model consisted of the fatigue type, bode, age and gender, where fatigue-type and BODE were entered as continuous variables, but the proportional hazard assumption was not met. Moreover, no transformation of the predictors of interest improved the model sufficiently. Therefore fatigue experiences, fatigue impacts and bode were trichotomised. The resulting models satisfied the proportional hazards assumption. Sensitivity analyses were also conducted and reported to examine the robustness of the results, where fatigue experiences, fatigue impacts and BODE are dichotomised and divided into quartiles. The associations between length of stay and each fatigue outcome were similarly assessed using multivariable negative binomial regression, adjusting for age, gender and BODE, to account for possible overdispersion.

To assess how the severity of fatigue in COPD related to other groups with chronic conditions the mean levels of fatigue between groups were evaluated using multiple linear regression, adjusting for age and gender. Fatigue experiences and fatigue impacts were examined separately.
Residual diagnostic checks for normality and homoscedasticity were conducted to ensure model validity. A p-value less than 0.05 (two-tailed) was considered statistically significant. All statistical analyses were performed on Intercooled Stata 11 for windows (StataCorp LP).

Results

Patient Characteristics

Of the 100 consecutive patients attending assessment clinics prior to entry to a pulmonary rehabilitation program, missing data in the dyspnoea variable (MMRC score) precluded BODE score calculation in 17 of the patients examined, thus only 83 complete respiratory-patient datasets could be generated. These 83 patients constituted the sample analysed in tables 2 and 3. No statistically significant differences were identified between those with complete data and those with missing MMRC scores. During the 20 month follow-up, six patients died. The mean FEV$_1$ of 53% of predicted (SD =21) shows that by GOLD criteria [18], the COPD patients on average had moderate disease, although there was a wide range of FEV1 severity (Table 1). On average our patient sample reported their dyspnoea to be between ‘walk slower than contemporaries on level ground because of breathlessness’ and ‘have to stop for breath when walking at own pace’ (mean: mMRC 2.3; SD:1.2). During the six minute walk test 36% of the patients walked less than 350 metres (mean: 388, SD: 117), with distances below 350 metres considered to indicate levels of functional impairment that is of prognostic significance to mortality [19]. The average BODE score was 3.5 (SD: 2.4). For the COPD patients, the average fatigue experiences score was 48% (SD: 17) of the available range; the average fatigue impacts score was 41% (SD: 21) of the available range.
Twenty-four percent of the COPD patients had at least one hospital admission during the 20 months of follow-up; 58% of those hospitalised during follow-up were admitted on multiple occasions (range: 1-11). There were a total of 58 admissions. The median length of stay was 7 days (range 1-52, IQR 4-14).

For the COPD patients, significant relationships were present between fatigue experiences score and BODE score ($R^2=.38; p=0.001$) and between fatigue impacts score and BODE score ($R^2=.49; p=0.001$). These associations are medium by Cohen’s criteria [20].

Multivariable analyses showed that for fatigue experiences, the most severely fatigued third of the sample was at greater risk of hospitalisation than the lowest (HR: 11.4 95%CI 2.56-50.53, Table 2) and middle thirds (HR: 5.0 95%CI 1.40-18.12). Compared to the lowest third of patients, the third of patients reporting the most intense scores on fatigue impacts showed a 13.6 fold increase in risk of hospitalisation (95%CI 2.50-74.20). For fatigue impacts, no significant increase in risk of hospitalisation existed when the middle third of patients was compared to the two extremes. Sensitivity analyses showed that when the fatigue data were dichotomised, the more fatigued participants experienced higher rates of hospitalisation (fatigue experiences HR: 5.4 95%CI 1.51-19.03; fatigue impacts HR: 5.0 95%CI 1.24-20.44). The only significant differences identified in the quartiled data were between the lowest and third quartiles (fatigue experiences HR: 10.2 95%CI 1.70-61.66; fatigue impacts HR: 7.2 95%CI 1.17-44.78). Length of hospital stay increased by a factor of almost 4 for every unit increase in fatigue experiences.
(IRR: 3.72 95%CI 1.37-4.84%, Table 3) and by over 2 for every unit increase in fatigue impacts (IRR: 2.36 95%CI 0.43-2.90%).

After controlling for age and gender differences, there was no significant difference between the ICFS fatigue scores of our population of COPD patients (fatigue experiences: 4.7 (95% CI: 3.7-5.8); fatigue impacts: 4.2 (95% CI: 3.0-5.4)) and the populations of patients with colorectal cancer awaiting surgery (fatigue experiences: 4.5 (95% CI: 3.5-5.5); fatigue impacts: 3.5 (95% CI: 2.3-4.7)) and HIV-positive patients (fatigue experiences: 5.3 (95% CI: 3.9-6.7); fatigue impacts: 4.5 (95% CI: 2.9-6.1)).
Discussion

From the patient’s perspective, fatigue is a prominent element in the symptoms experienced as a consequence of COPD [1]. However there is little quantitative evidence supporting the clinical relevance of fatigue reports. Beyond ‘clinical gut feeling’, clinicians have few sources of information to guide their interpretation of what patients mean when they report subjective fatigue. This study confirms that fatigue reports are systematically related to markers of COPD disease severity. However of greater clinical importance our results show that, independent of disease severity, fatigue is a strong predictor of hospitalisation risk, which is itself an important driver of impaired quality of life, negative impact on self and family, escalation of personal and societal costs, and ongoing instability and mortality.

It is well established that COPD patients experience high rates of hospital admission [21, 22], inducing a substantial economic burden [23, 24]. Identifying signals that predict future hospitalisation risk in COPD patients is therefore of both clinical and economic relevance. There is mounting evidence that BODE scores predict outcomes such as hospitalisations and mortality [25-27]. Our work shows that fatigue data independently predicts hospitalisation risk.

In the model including fatigue experiences, a BODE score within the upper extreme third was associated with a hospitalisation risk 5 fold greater than the 20-month risk for those with a BODE score within the lowest third. Comparisons between the extreme thirds of the fatigue data identified 11 and 13 fold differences in the risk of hospitalisation for fatigue experiences and fatigue impacts respectively. Post hoc analyses examining the relationship between the fatigue data and length of hospital stay also supported the strong discriminating role of fatigue reports regarding duration of hospitalisations.
We found significant relationships between fatigue and disease severity, as measured by BODE, in COPD patients attending pulmonary rehabilitation. As expected, when BODE score increased so did fatigue scores. Causal mechanisms explaining this are likely, at least in part, to lie in the growing evidence suggesting that COPD causes a state of systemic inflammation [28, 29]. It is well recognised that inflammation can induce a behavioural profile termed ‘sickness behaviour’ [30]. In humans cytokine-induced sickness behaviour includes subjective reports of lethargy and tiredness [31], while experimental animal models show behavioural markers of fatigue [32]. While some people with COPD have measurable systemic inflammation out of proportion to the severity of their airflow limitation, there is an overall association between COPD severity and derangement of inflammatory processes [33, 34]. There are of course other explanations for fatigue in COPD patients, such as the high oxygen cost of breathing especially in hyperinflated patients or hypoxaemia limiting activities.

Existing literature has shown that COPD patients report greater fatigue than the general population [35-37]. However, the severity of fatigue between COPD patients and other clinical populations has rarely been examined. Fatigue experiences and impacts reported by our COPD population were of similar intensity to those reported by colorectal cancer patients awaiting surgery and by HIV-positive patients [11, 12]. The occurrence of chronic inflammation that is common to these three situations [38, 39] may help to explain this observation. Other common explanations may include, fear and other psychological reactions to potentially or ultimately fatal diseases; or factors such as sleep disturbance and disruption to circadian rhythms [40,41].
There are several limitations of the current study. The COPD patients are all patients who were included in a pulmonary rehabilitation program and therefore a selection of more symptomatic COPD patients. The results of this study may not apply to the whole COPD population. Also, admissions to private hospitals or to hospitals other than the patients’ local tertiary centers were not recorded. However, given the geography of Adelaide and general patient flows we anticipate few cases would have been affected by this issue. Finally, it is known that pulmonary rehabilitation influences admission rates in patients with COPD [42,43], so it is possible that our admission rates will be lower than a population who has not attended pulmonary rehabilitation.

Overall, more research is needed to understand the clinical meaning attributable to patient reports of fatigue. Our results particularly those relating to hospitalisation risk, while suggesting clinical importance, require replication. Work to investigate potential causal mechanisms is also of importance. Other directions for future research include establishment of ICFS norm values using a healthy sample in adults and elderly patients, and investigation of whether the ICFS tool is sensitive enough to capture changes in fatigue reports during periods of clinical change, such as during infective exacerbations of COPD or following interventions such as pharmacological treatments or pulmonary rehabilitation. Understanding the relationship between fatigue and BODE will be of special importance. Our data show that fatigue and BODE scores share only 30 to 50% of their variation, which implies that fatigue reports capture information about patient state that is not summarised in the BODE index and vice versa. Identifying what underlies this unshared element of variance will be important to understanding how fatigue contributes to hospitalisation risk separately from BODE.
In conclusion, this study has shown that fatigue reports are significantly related to COPD severity in COPD patients attending a pulmonary rehabilitation programme and also that fatigue scores capture additional information. Our sample of COPD patients reported fatigue intensity that was similar to that reported by colorectal cancer patients and by HIV-positive patients. Finally, fatigue reports were shown to significantly predict hospitalisation risk and length of hospital admission.
References


<table>
<thead>
<tr>
<th>Participant Characteristics</th>
<th>COPD patients</th>
<th>HIV-positive patients</th>
<th>Colorectal cancer patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>SD</td>
<td>N</td>
<td>Mean</td>
</tr>
<tr>
<td>Male</td>
<td>49</td>
<td>83</td>
<td>Male</td>
</tr>
<tr>
<td>Age</td>
<td>72</td>
<td>9.3</td>
<td>Age</td>
</tr>
<tr>
<td>Fatigue experiences</td>
<td>4.7</td>
<td>1.6</td>
<td>Fatigue experiences</td>
</tr>
<tr>
<td>Fatigue impacts</td>
<td>4.0</td>
<td>1.9</td>
<td>Fatigue impacts</td>
</tr>
<tr>
<td>FEV$_1$ (% predicted)</td>
<td>51</td>
<td>21</td>
<td>CD4 count (cell/mm$^3$)</td>
</tr>
<tr>
<td>GOLD class I</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOLD class II</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOLD class III</td>
<td>31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOLD class IV</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMRC</td>
<td>2.2</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>6MWD (metre)</td>
<td>388</td>
<td>115</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td>27</td>
<td>5.3</td>
<td></td>
</tr>
<tr>
<td>BODE Score</td>
<td>3.5</td>
<td>2.4</td>
<td></td>
</tr>
</tbody>
</table>
FEV₁=Forced Expiratory Volume in One Second; mMRC =modified Medical Research Council dyspnoea scale; 6MWD=Six Minute Walk Distance; BMI=Body Mass Index

* it is known that no patient in the series had a diagnosis made of metastatic cancer.

Table 2 Risk of hospitalisation in COPD patients over 20 months

<table>
<thead>
<tr>
<th></th>
<th>Univariate analyses</th>
<th>Multivariate models</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95%CI</td>
</tr>
<tr>
<td><strong>Fatigue Experiences Model</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue Experiences highest vs. lowest third</td>
<td>18.24***</td>
<td>4.00-83.67</td>
</tr>
<tr>
<td>Fatigue Experiences middle vs. lowest third</td>
<td>3.29</td>
<td>0.88-12.30</td>
</tr>
<tr>
<td>BODE highest vs. lowest third</td>
<td>5.83</td>
<td>0.20-167.43</td>
</tr>
<tr>
<td>BODE middle vs. lowest third</td>
<td>3.04</td>
<td>0.76-12.21</td>
</tr>
<tr>
<td>Age</td>
<td>0.75</td>
<td>0.27-2.05</td>
</tr>
<tr>
<td>Male gender</td>
<td>1.88</td>
<td>0.53-6.59</td>
</tr>
<tr>
<td><strong>Fatigue Impacts Model</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue Impacts highest vs. lowest third</td>
<td>22.25***</td>
<td>4.38-113.48</td>
</tr>
<tr>
<td>Fatigue Impacts middle vs. lowest third</td>
<td>4.25</td>
<td>0.90-20.08</td>
</tr>
<tr>
<td>BODE highest vs. lowest third</td>
<td>5.83</td>
<td>0.20-167.43</td>
</tr>
<tr>
<td>BODE middle vs. lowest third</td>
<td>3.04</td>
<td>0.76-12.21</td>
</tr>
<tr>
<td>Age</td>
<td>0.75</td>
<td>0.27-2.05</td>
</tr>
<tr>
<td>Male gender</td>
<td>1.88</td>
<td>0.53-6.59</td>
</tr>
</tbody>
</table>

HR=Hazard Ratio.
* p<0.05, ** p<0.01, *** p<0.001
N=83
Table 3 Predicting Length of Hospital Admission in COPD Patients

<table>
<thead>
<tr>
<th></th>
<th>Univariate analyses</th>
<th></th>
<th>Multivariate models</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IRR</td>
<td>95%CI</td>
<td>IRR</td>
<td>95%CI</td>
</tr>
<tr>
<td>Fatigue Experiences Model</td>
<td>Fatigue Experiences</td>
<td>4.19** 2.75-6.36</td>
<td>3.72** 2.37-5.84</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BODE</td>
<td>1.56 0.77-3.17</td>
<td>1.42 0.81-2.47</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age</td>
<td>0.50* 0.31-0.82</td>
<td>0.85 0.44-1.65</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Male gender</td>
<td>1.53 0.33-7.0</td>
<td>2.11 0.81-5.49</td>
<td></td>
</tr>
<tr>
<td>Fatigue Impacts Model</td>
<td>Fatigue Impacts</td>
<td>2.48** 1.46-4.21</td>
<td>2.36** 1.43-3.90</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BODE</td>
<td>1.56 0.77-3.17</td>
<td>1.21 0.51-2.90</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age</td>
<td>0.50* 0.31-0.82</td>
<td>0.88 0.42-1.84</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Male gender</td>
<td>1.53 0.33-7.0</td>
<td>4.29* 1.12-16.50</td>
<td></td>
</tr>
</tbody>
</table>

IRR=Incidence rate ratio.
* p<0.05, ** p<0.001
N=83